LONDON (ShareCast) - (Sharecast News) - Ixico announced two new agreements worth a combined £1.2m on Wednesday, including a contract to support the validation of a diagnostic blood test and an extension to an existing Alzheimer's disease clinical trial.
The AIM-traded neuroscience analytics group said the new contract, signed with a leading global biopharma company, would run for just under three years and involve the use of its AI-driven platform to analyse a prospective blood-based biomarker for an undisclosed neurodegenerative condition.

It said the contract extension added further activities to an ongoing Alzheimer's disease study that Ixico has been supporting, reinforcing the company's long-term order book.

"The new contract win marks our continued expansion and expertise in the blood-based biomarker field," said chief executive Bram Goorden.

"The sustained period of contract extensions culminating in this important AD clinical trial, demonstrates the demand for Ixico's services and expertise, the consistent quality of our work, and the value we provide to major biopharma clients."

Ixico said the wins extended its positive commercial momentum and aligned with its 'Innovate, Lead, Scale' strategy, aimed at accelerating global growth and expanding its role in biomarker development for neurological disorders.

At 1141 BST, shares in Ixico were up 2.08% at 12.25p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE